Mnemo Therapeutics, a biotech working to refine and improve CAR-T cells, has tapped former Bayer EVP Robert LaCaze as its new CEO, effective May 1.
PARIS, Feb. 23, 2022 /PRNewswire/ -- Mnemo Therapeutics, a biotechnology company developing next-generation T cell therapies, today announced the appointment of Robert LaCaze as the company's new chief executive officer effective May 1. A recognized oncology leader with a focus on driving innovation and value for patients, Mr. LaCaze joins Mnemo from Bayer, where he served as executive vice president and head of the company's Oncology Strategic Business Unit. He was also a member of the Executive Committee of Bayer Pharmaceutical AG. Founding CEO Alain Maiore will continue in the role until May 1, and then will take on the role of chief operating officer.